Retrospective Analysis of the French National Cohort of Patients With GAD Antibodies and Cerebellar Ataxia

Recruiting

• Conditions: GAD-receptor Antibodies-associated Encephalitis
• Interventions: Other: GAD patients

• Registration Number: NCT06334900
• Lead Sponsor: Hospices Civils de Lyon

Brief Summary

Glutamic acid decarboxylase (GAD) is an enzyme whose function in the body is to decarboxylate glutamate to GABA. GAD65 antibodies (GAD65Ab) have been associated with type-1 diabetes (80% of new-onset patients) and various neurological conditions, mainly stiff-person syndrome (SPS/PERM), cerebellar ataxia (CA), limbic encephalitis (LE) and temporal lobe epilepsy. These syndromes all seem to result from a reduced transmission of GABA. These neurological conditions are rare and can cause symptoms like confusion, memory loss, muscle stiffness, muscle spasms, behavioural disorders, and pharmacoresistant epilepsy. When finding high levels of GAD65-Ab in the serum, a cerebrospinal fluid (CSF) sample should be taken to look for oligoclonal IgG bands and intrathecal GAD-Ab production to prove an auto-immune cause for the various neurological symptoms.

Detailed Description

Not available

Study Timeline

• Study Start: 2023-10-01
• Primary Completion: 2024-01-01
• Status Verified: 2024-03
• Study First Submitted: 2024-03-21
• Study First Submitted QC: 2024-03-21
• Last Update Submitted: 2024-03-21
• Study First Posted: 2024-03-28
• Last Update Posted: 2024-03-28
• Study Completion: 2024-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

• neurological symptoms with GAD antibody
• GAD antibody in sera and/or CSF
• patient with cerebellar ataxia

Exclusion Criteria

• tested positive to another antibody.
• no data
• any test in paraneoplastic neurological syndrome and autoimmune encephalitis center

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Anti-GAD encephalitis	GAD patients	This is a non-interventional study involving clinical data. This data are information of medical follow up on patient like diagnosis, symptoms, biological results, cancer, treatments.

Primary Outcome Measures

Name	Time	Method
GAD Patient	Baseline	Description of clinical data in patients with cerebellar syndrome associated with anti-GAD antibodies

Trial Locations

Locations (1)

Hôpital Neurologique Pierre Wertheimer / Groupement Hospitalier Est; 🇫🇷 Bron, France